Growth hormone and testosterone in heart failure therapy

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 11, 2010, Pages 1835-1844

  Agarwal, Megha ^a   Naghi, Jesse ^a   Philip, Kiran ^a   Phan, Anita ^a   Willix Jr, Robert D ^c   Schwarz, Ernst R ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Cenegenics Medical Institute   (United States)

Author keywords

Growth hormone; Heart failure; IGF; Insulin like growth factor; Review; Testosterone; Therapy; Treatment

Indexed keywords

GROWTH HORMONE; OXYMETHOLONE; TESTOSTERONE;

ANDROGEN DEFICIENCY; BREAST CANCER; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DISEASE COURSE; DISEASE EXACERBATION; FLUID RETENTION; GYNECOMASTIA; HEART FAILURE; HEMATOCRIT; HIRSUTISM; HORMONE RESISTANCE; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; ORTHOSTATIC HYPOTENSION; PROSTATE CANCER; RASH; REVIEW; RISK REDUCTION; SIDE EFFECT; SURVIVAL; SYMPTOM; TREATMENT OUTCOME; PHYSIOLOGY;

GROWTH HORMONE; HEART FAILURE; HUMANS; TESTOSTERONE;

EID: 77954765306     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.485615     Document Type: Review

References (95)

1. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112:e154-235
2. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002;347:1397-1402 (Pubitemid 35239711)
3. Pugh PJ, Jones RD, Jones TH, Channer KS. Heart failure as an inflammatory condition: potential role for androgens as immune modulators. Eur J Heart Fail 2002;4:673-680
4. Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabolic/ anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997;96:526-534
5. Chaggar PS, Malkin CJ, Shaw SM, et al. Neuroendocrine effects on the heart and targets for therapeutic manipulation in heart failure. Cardiovasc Ther Fall 2009;27:187-193
6. von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview. Pharmacol Ther 2009;121:227-252
7. Anker SD, Clark AL, Kemp M, et al. Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J Am Coll Cardiol 1997;30:997-1001
8. Niebauer J, Pflaum CD, Clark AL, et al. Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. J Am Coll Cardiol 1998;32:393-397
9. Kontoleon P, Anastasiou-Nana M, Papapetrou P, et al. Hormonal profile in patients with congestive heart failure. Int J Cardiol 2003;87:179-183
10. Perrot A, Ranke MB, Dietz R, Osterziel KJ. Growth hormone treatment in dilated cardiomyopathy. J Card Surg 2001;16:127-131
11. Climent V, Marin F, Pico A. Pharmacologic therapy in growth hormone disorders and the heart. Curr Med Chem 2007;14:1399-1407
12. Colao A. The GH-IGF-I axis and the cardiovascular system: clinical implications. Clin Endocrinol (Oxf) 2008;69:347-358
13. Sacca L. Growth hormone: a newcomer in cardiovascular medicine. Cardiovasc Res 1997;36:3-9
14. Wahlander H, Isgaard J, Jennische E, Friberg P. Left ventricular insulin-like growth factor I increases in early renal hypertension. Hypertension 1992;19:25-32
15. Delafontaine P. Insulin-like growth factor I and its binding proteins in the cardiovascular system. Cardiovasc Res 1995;30:825-834
16. Guse A, Kiess W, Funk B, et al. Identification and characterization of insulin-like growth factor receptors on adult rat cardiac myocytes: linkage to inositol 1, 4, 5-trisphosphate formation. Endocrinology 1992;130:145-151
17. Mathews L, Enberg B, Norstedt G. Regulation of rat growth hormone receptor gene expression. J Biol Chem 1989;264:9905-9910
18. Ito H, Hiroe M, Hirata Y, et al. Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation 1993;87:1715-1721
19. Chen DB, Wang L, Wang PH. Insulin-like growth factor I retards apoptotic signaling induced by ethanol in cardiomyocytes. Life Sci 2000;67:1683-1693
20. Cittadini A, Ishiguro Y, Stromer H, et al. Insulin-like growth factor-1 but not growth hormone augments mammalian myocardial contractility by sensitizing the myofilament to Ca2+ through a wortmannin-sensitive pathway: studies in rat and ferret isolated muscles. Circ Res 1998;83:50-59
21. Tsukahara H, Gordienko D, Tonshoff B, et al. Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int 1994;45:598-604
22. Bayes-Genis A, Conover C, Schwartz R. The insulin-like growth factor axis: a review of atherosclerosis and restenosis. Circ Res 2000;86:125-130
23. Cittadini A, Saldamarco L, Marra AM, et al. Growth hormone deficiency in patients with chronic heart failure and beneficial effects of its correction. J Clin Endocrinol Metab 2009;94:3329-3336
24. Osterziel KJ, Blum WF, Strohm O, Dietz R. The severity of chronic heart failure due to coronary artery disease predicts the endocrine effects of short-term growth hormone administration. J Clin Endocrinol Metab 2000;85:1533-1539
25. Anker SD, Volterrani M, Pflaum CD, et al. Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J Am Coll Cardiol 2001;38:443-452
26. Petretta M, Colao A, Sardu C, et al. NT-proBNP, IGF-I and survival in patients with chronic heart failure. Growth Horm IGF Res 2007;17:288-296
27. Lund LH, Freda P, Williams JJ, et al. Growth hormone resistance in severe heart failure resolves after cardiac transplantation. Eur J Heart Fail 2009;11:525-528
28. Anker SD, Negassa A, Coats AJS, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 2003;361:1077-1083
29. Delafontaine P, Brink M. The growth hormone and insulin-like growth factor 1 axis in heart failure. Ann Endocrinol (Paris) 2000;61:22-26
30. Osterziel KJ, Ranke MB, Strohm O, Dietz R. The somatotrophic system in patients with dilated cardiomyopathy: relation of insulin-like growth factor-1 and its alterations during growth hormone therapy to cardiac function. Clin Endocrinol 2000;53:61-68
31. Sacca L. Heart failure as a multiple hormonal deficiency syndrome. Circ Heart Fail 2009;2:151-156
32. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 1996;93:841-842
33. Abelmann WH. Classification and natural history of primary myocardial disease. Prog Cardiovasc Dis 1984;27:73-94
34. Komajda M, Charron P. Idiopathic cardiomyopathies. Rev Prat 2002;52:1664-1670
35. Mulumba M, Cemeus C, Dumont L, et al. Recombinant bovine growth hormone-induced reduction of atrial natriuretic peptide is associated with improved left ventricular contractility and reverse remodeling in cardiomyopathic UM-X7.1 hamsters with congestive heart failure. Growth Horm IGF Res 2007;17:96-103
36. Fazio S, Sabatini D, Capaldo B, et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996;334:809-814 (Pubitemid 26099602)
37. Cittadini A, Stromer H, Katz S, et al. Differential cardiac effects of growth hormone and insulin-like growth factor1 in the rat: a combined in vivo and in vitro evaluation. Circulation 1996;93:800-809
38. Jose VJ, Zechariah TU, George P, Jonathan V. Growth hormone therapy in patients with dilated cardiomyopathy: preliminary observations of a pilot study. Indian Heart J 1999;51:183-185
39. Osterziel KJ, Strohm O, Schuler J, et al. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 1998;351:1233-1237
40. Napoli R, Guardasole V, Matarazzo M, et al. Growth hormone corrects vascular dysfunction in patients with chronic heart failure. J Am Coll Cardiol 2002;39:90-95
41. Le Corvoisier P, Hittinger L, Chanson P, et al. Cardiac effects of growth hormone treatment in chronic heart failure: a meta-analysis. J Clin Endocrinol Metab 2007;92:180-185
42. Drexler H, Hayoz D, Munzel T, et al. Endothelial function in congestive heart failure. Am Heart J 1993;126:761-764
43. Napoli R, Guardasole V, Angelini V, et al. Acute effects of growth hormone on vascular function in human subjects. J Clin Endocrinol Metab 2003;88:2817-2820
44. Volterrani M, Desenzani P, Lorusso R, et al. Haemodynamic effects of intravenous growth hormone in congestive heart failure. Lancet 1997;349:1067-1068 (Pubitemid 27158254)
45. Isgaard J, Kujacic V, Jennische E, et al. Growth hormone improves cardiac function in rats with experimental myocardial infarction. Eur J Clin Invest 1997;27:517-525 (Pubitemid 27288363)
46. Tajima M, Weinberg E, Bartunek J, et al. Treatment with growth hormone enhances contractile reserve and intracellular calcium transients in myocytes from rats with postinfarction heart failure. Circulation 1999;99:127-134
47. Timsit J, Riou B, Bertherat J, et al. Effects of chronic growth hormone hypersecretion on intrinsic contractility, energetics, isomyosin pattern, and myosin adenosine triphosphatase activity of rat left ventricle. J Clin Invest 1990;86:507-515
48. Henry L. Left ventricular systolic dysfunction and ischemic cardiomyopathy. Crit Care Nurs Q 2003;26:16-21
49. Delahaye F, de Gevigney G. Epidemiology and natural history of cardiac failure. Rev Prat 1997;47:2114-2117
50. Jayasankar V, Pirolli TJ, Bish LT, et al. Targeted overexpression of growth hormone by adenoviral gene transfer preserves myocardial function and ventricular geometry in ischemic cardiomyopathy. J Mol Cell Cardiol 2004;36:531-538
51. Follath F. Ischemic versus non-ischemic heart failure: should the etiology be determined? Heart Fail Monit 2001;1:122-125
52. Genth-Zotz S, Zotz R, Geil S, et al. Recombinant growth hormone therapy in patients with ischemic cardiomyopathy: effects on hemodynamics, left ventricular function, and cardiopulmonary exercise capacity. Circulation 1999;99:18-21
53. Parissis JT, Adamopoulos S, Karatzas D, et al. Growth hormone-induced reduction of soluble apoptosis mediators is associated with reverse cardiac remodelling and improvement of exercise capacity in patients with idiopathic dilated cardiomyopathy. Eur J Cardiovasc Prev Rehabil 2005;12:164-168
54. Cittadini A, Isgaard J, Monti MG, et al. Growth hormone prolongs survival in experimental postinfarction heart failure. J Am Coll Cardiol 2003;41:2154-2163
55. Jin H, Yang R, Lu H, et al. Effects of early treatment with growth hormone on infarct size, survival, and cardiac gene expression after acute myocardial infarction. Growth Horm IGF Res 2002;12:208-215
56. Seiva FR, Ebaid GM, Castro AV, et al. Growth hormone and heart failure: oxidative stress and energetic metabolism in rats. Growth Horm IGF Res 2008;18:275-283
57. Adamopoulos S, Parissis JT, Paraskevaidis I, et al. Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy. Eur Heart J 2003;24:2186-2196
58. Adamopoulos S, Parissis JT, Georgiadis M, et al. Growth hormone administration reduces circulating proinflammatory cytokines and soluble Fas/soluble Fas ligand system in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy. Am Heart J 2002;144:359-364
59. Smit JW, Janssen YJ, Lamb HJ, et al. Six months of recombinant human GH therapy in patients with ischemic cardiac failure does not influence left ventricular function and mass. J Clin Endocrinol Metab 2001;86:4638-4643
60. van Thiel SW, Smit JW, de Roos A, et al. Six-months of recombinant human GH therapy in patients with ischemic cardiac failure. Int J Cardiovasc Imaging 2004;20:53-60
61. Spallarossa P, Rossettin P, Minuto F, et al. Evaluation of growth hormone administration in patients with chronic heart failure secondary to coronary artery disease. Am J Cardiol 1999;84:430-433
62. Isgaard J, Bergh CH, Caidahl K, et al. A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur Heart J 1998;19:1704-1711
63. Fazio S, Palmieri EA, Affuso F, et al. Effects of growth hormone on exercise capacity and cardiopulmonary performance in patients with chronic heart failure. J Clin Endocrinol Metab 2007;92:4218-4223
64. Demers C, McKelvie RS. Growth hormone therapy in heart failure: a novel therapy worthy of further consideration? Expert Opin Investig Drugs 2005;14:1009-1018
65. Bocchi EA, Massuda Z, Guilherme G, et al. Growth hormone for optimization of refractory heart failure treatment. Arq Bras Cardiol 1999;73:391-398
66. Bocchi E, Moura L, Guimaraes G, et al. Beneficial effects of high doses of growth hormone in the introduction and optimization of medical treatment in decompensated congestive heart failure. Int J Cardiol 2006;110:313-317
67. Fukuda I, Hizuka N, Murakami Y, et al. Clinical features and therapeutic outcomes of 65 patients with acromegaly at Tokyo Women's Medical University. Intern Med 2001;40:987-992
68. Sullivan D, Carter W, Warr W, Williams L. Side effects resulting from the use of growth hormone and insulin-like growth factor-I as combined therapy to frail elderly patients. J Gerontol A Biol Sci Med Sci 1998;53:M183-7
69. Kontoleon PE, Anastasiou-Nana MI, Papapetrou PD, et al. Hormonal profile in patients with congestive heart failure. Int J Cardiol 2003;87:179-183
70. Malkin CJ, Pugh PJ, West JN, et al. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 2006;27:57-64
71. Aukrust P, Ueland T, Gullestad L, Yndestad A. Testosterone: a novel therapeutic approach in chronic heart failure? J Am Coll Cardiol 2009;54:928-929
72. Bassil N, Alkaade S, Morley JE. The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag 2009;5:427-448
73. Jankowska EA, Biel B, Majda J, et al. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation 2006;114:1829-1837
74. Yeap BB. Testosterone and ill-health in aging men. Nat Clin Pract Endocrinol Metab 2009;5:113-121
75. Yeap BB, Wilce JA, Leedman PJ. The androgen receptor mRNA. Bioessays 2004;26:672-682
76. Rahman F, Christian HC. Non-classical actions of testosterone: an update. Trends Endocrinol Metab 2007;18:371-378
77. Jones RD, Pugh PJ, Jones TH, Channer KS. The vasodilatory action of testosterone: a potassium-channel opening or a calcium antagonistic action? Br J Pharmacol 2003;138:733-744
78. Scragg JL, Dallas ML, Peers C. Molecular requirements for L-type Ca2+ channel blockade by testosterone. Cell Calcium 2007;42:11-15
79. Malkin CJ, Jones RD, Jones TH, Channer KS. Effect of testosterone on ex vivo vascular reactivity in man. Clin Sci (Lond) 2006;111:265-274
80. Pugh PJ, Jones TH, Channer KS. Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J 2003;24:909-915
81. Webb CM, McNeill JG, Hayward CS, et al. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 1999;100:1690-1696
82. English KM, Steeds RP, Jones TH, et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation 2000;102:1906-1911
83. Malkin CJ, Pugh PJ, Morris PD, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 2004;90:871-876
84. Cornoldi A, Caminiti G, Marazzi G, et al. Effects of chronic testosterone administration on myocardial ischemia, lipid metabolism and insulin resistance in elderly male diabetic patients with coronary artery disease. Int J Cardiol 2009. [Epub ahead of print]
85. Tomoda H. Effect of oxymetholone on left ventricular dimensions in heart failure secondary to idiopathic dilated cardiomyopathy or to mitral or aortic regurgitation. Am J Cardiol 1999;83:123-5, A129
86. Pugh PJ, Jones RD, West JN, et al. Testosterone treatment for men with chronic heart failure. Heart 2004;90:446-447
87. Morales FJ, Martinez A, Mendez M, et al. A shuttle walk test for assessment of functional capacity in chronic heart failure. Am Heart J 1999;138:291-298
88. Morales FJ, Montemayor T, Martinez A. Shuttle versus six-minute walk test in the prediction of outcome in chronic heart failure. Int J Cardiol 2000;76:101-105
89. Caminiti G, Volterrani M, Iellamo F, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009;54:919-927
90. Arena R, Myers J, Abella J, et al. Development of a ventilatory classification system in patients with heart failure. Circulation 2007;115:2410-2417
91. El-Mas MM, Afify EA, Mohy El-Din MM, et al. Testosterone facilitates the baroreceptor control of reflex bradycardia: role of cardiac sympathetic and parasympathetic components. J Cardiovasc Pharmacol 2001;38:754-763
92. Mortara A, La Rovere MT, Pinna GD, et al. Arterial baroreflex modulation of heart rate in chronic heart failure: clinical and hemodynamic correlates and prognostic implications. Circulation 1997;96:3450-3458
93. Kazi M, Geraci SA, Koch CA. Considerations for the diagnosis and treatment of testosterone deficiency in elderly men. Am J Med 2007;120:835-840
94. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006;91:1995-2010
95. Toogood A, Jones J, O'Neill P, et al. The diagnosis of severe growth hormone deficiency in elderly patients with hypothalamic-pituitary disease. Clin Endocrinol 1998;48:569-576